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Available online at www.sciencedirect.comGenome sequencing of tumors provides a wealth of information
on mutations and structural variations, instilling hope that this
data can be used to predict individual tumor progression and
response to treatment. Yet currently, our ability to predict the
functional consequences of these aberrations remains poor.
How do cancer-associated mutations give rise to the hallmark
phenotypes of cancer? Recently, information about the genetic
makeup of cancer cells has been combined with novel
functional genomics approaches to identify novel targets,
exploit synthetic lethality and explore the rewiring of cellular
pathways. Here, we highlight recent developments revealing
the hidden landscape of genetic interactions in model
organisms and cancer cells, a key step toward personalized
cancer diagnostics and therapy.
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Introduction
If you wear glasses or contact lenses, you are already
enjoying the benefits of personalized medicine. Eye-care
specialists can precisely diagnose your degree of near-
sightedness or farsightedness and prescribe corrective
measures tailored specifically to your individual needs,
including, for example, spectacles, lenses or laser eye
surgery, to restore 20/20 vision. This remarkable combi-
nation of near-perfect disease stratification and indivi-
dualized treatment is so commonplace that we hardly
notice it any more.
By contrast, the much graver individual pathologies of
individual human tumors have only recently begun to be
revealed through advances in DNA sequencing technol-
ogy. Tumors originating from the same tissue frequently
Open access under CC BY-NC-ND license.Current Opinion in Genetics & Development 2012, 22:36–44 harbor aberrations affecting the same small set of path-
ways. For example, a systematic analysis of ovarian car-
cinomas showed recurrent somatic mutations in at least
ten genes, including well-known cancer genes, for
example, TP53, BRCA1 and/or BRCA2, NF1, RB1 or
CDK12 [1]. In addition, tumor-specific DNA copy num-
ber variations (CNVs), differential gene expression and
promoter methylation events were detected. Together,
these aberrations frequently affected the same signaling
pathways, for example, the RB, PI3-kinase or NOTCH
pathways, as well as the regulation of cell cycle pro-
gression and DNA repair [1]. Strikingly, a subset of these
pathways was also highlighted in a large-scale analysis of
glioblastoma, harboring mutations or CNVs in RAS/PI3-
kinase, p53 and RB pathways [2].
Beyond this common spectrum of mutations, each
patient’s tumor also displays a large number of unique
genetic characteristics – the sum of inter-individual varia-
bility already present in the germline and additional
aberrations accumulated during tumor progression
[1,2,3,4]. They also influence cancer-specific pheno-
types or the predisposition to resistance toward treatment
through complex functional interactions. As sequencing
technologies reach the clinic [5,6–9] patients can be
stratified into smaller and smaller groups based on the
correlation between these genetic and epigenetic bio-
markers and clinical data. This will raise exciting oppor-
tunities for individualized treatments – but also create
novel challenges for drug development. How can treat-
ments and tumors be individually matched to achieve the
best possible outcome?
Searching for similarities: screening human
cancer cell line panels
At the time of writing, 464 genes had been annotated as
causally implicated in cancer, representing 2% of all
protein-coding genes (Source: Cancer Gene Census,
[10]). The vast majority of them has been studied in
one or more of 800 established tissue culture models of
human cancer, for example the ‘NCI-60’ lines extensively
used in drug development pipelines [11]. In depth
characterization of CNVs has revealed considerable vari-
ation between lines [12,13], offering the opportunity to
study the effects of different genetic backgrounds in
high-throughput functional genomics experiments.
In a recent study, Cheung et al. performed large-scale
loss-of-function experiments with more than 100 human
cancer cell lines, including 25 established from ovarianwww.sciencedirect.com
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with more than 54 000 shRNAs, the study assessed and
compared the effect of RNAi-mediated gene knockdown
of more than 11 000 genes on cell growth and survival
[14]. The results revealed stark differences between the
lines, consistent with a strong influence of genetic and
epigenetic background on the phenotype of the targeted
genes.
To demonstrate the quality of their dataset, Cheung et al.
subdivided their dataset along the mutational status of
KRAS, BRAF and PIK3CA, genes frequently mutated in
human cancers. Cells harboring such activated oncogenes
frequently depend on their continued activity to maintain
a malignant phenotype, a phenomenon called ‘oncogene
addiction’ [15]. Reassuringly, comparing the phenotypes
of mutant and wildtype cell lines consistently pinpointed
the known oncogene – KRAS, BRAF or PIK3CA, respect-
ively – as specifically required for cell growth only in the
presence of the activating mutation.
Next, the researchers split their dataset according to the
cell lines’ tissue of origin instead. Searching for genes
required specifically for proliferation and/or survival of
ovarian cancer cells revealed a set of 600 genes, a subset
of which had previously been reported to be amplified or
overexpressed in ovarian tumors (9.5%, 55/582). The
differential phenotype of one of them, the transcription
factor PAX8, was tested in eight ovarian cancer cell lines:
six of them relied on PAX8 expression for continued
growth.
In an independent study, Brough et al. employed a similar
strategy to identify differential growth and viability phe-
notypes in a panel of 34 breast cancer cell lines [16].
They recorded the effects of targeting 700 kinases with
pooled siRNAs and then split the dataset according to the
cell lines’ genetic markers, including common amplifica-
tion events (e.g. of the ERBB2 locus), known mutations
(e.g. in PIK3CA) or clinical subtypes (e.g. ER+/ER).
The researchers identified multiple RNAi phenotypes
specifically associated with cancer-associated genetic
aberrations: For example, cells lacking functional copies
of the tumor suppressor gene PTEN were particularly
dependent on genes controlling the mitotic spindle
assembly checkpoint and showed synthetic lethality with
siRNAs as well as small molecule inhibitors targeting the
checkpoint kinase TTK [16,17].
These examples highlight how the phenotypic differ-
ences within a panel of cell lines can reveal shared
dependencies of tumor subtypes, potentially providing
a highly selective set of candidate drug targets. Recently,
this approach has also been applied to address a long-
standing challenge in cancer research: how to kill tumors
carrying mutations in the gene most frequently affected
in human cancers – RAS?www.sciencedirect.com RAS: identification of new Achilles heels
More than 30% of tumors carry mutations in members of
the RAS small GTPase protein family, making NRAS,
KRAS and HRAS the most commonly affected genes in
human cancers [18]. Many cancer cell lines have also
remained addicted to constant activity of the Ras-sig-
naling pathway for maintaining a malignant phenotype,
rendering RAS (and other pathway members including,
for example, its downstream effector BRAF) highly
attractive drug targets [19]. Yet, so far attempts to
identify clinically useful small molecule inhibitors of
RAS have had little success [20].
Following the activation of oncogenes, such as RAS or
BRAF, cancer cells undergo a multi-step selection for
hallmark phenotypes including the evasion of apoptosis,
insensitivity to growth signals and unlimited reproductive
potential [21]. This requires an extensive re-wiring of
cellular signaling networks and places increased strain on
the cellular mechanisms coping with stress, including the
DNA-damage response and the detoxification of reactive
oxygen species [21]. In the presence of an activated
oncogene, genes of minor importance to the well-being
of normal cells may become essential – synthetically
lethal – specifically in cancer cells, providing novel oppor-
tunities for therapeutic intervention [22].
In 2009, Barbie et al. selected 19 different cell lines –
seven with mutant and 12 with wildtype KRAS alleles – to
identify genes displaying synthetic lethality with the
activated oncogene [23] (Figure 1a). By comparing cell
growth and viability after RNAi-mediated silencing of
kinases and phosphatases, the researchers identified 45
candidates (besides KRAS itself) as differentially
required in KRAS-mutant lines. Synthetic lethality with
TBK1, a non-canonical IkB kinase, was also observed in
secondary assays including an extended panel of cell lines
as well as isogenic cell models. Subsequent loss-of-func-
tion and gain-of-function experiments established a role
for TBK1 as a mediator of NF-kB survival signaling
downstream of KRAS, providing a mechanistic expla-
nation for the observed synthetic lethal phenotype
(Figure 1a).
A conceptionally similar study pinpointed the protein
kinase STK33 as another putative synthetic lethal inter-
actor of KRAS [24]. Yet, this result has remained con-
troversial, as the reported effects were not observed by
other researchers [25].
The systematic comparison of phenotypes across differ-
ent cell lines has the potential to reveal important corre-
lations between specific tumor properties (e.g. the
mutational status of the RAS locus, the tissue of origin
or the clinical stage) and the phenotypes of individual
genes. Yet, especially studies focusing on a small number
of lines may be biased by their selection. Even largeCurrent Opinion in Genetics & Development 2012, 22:36–44
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Quantitative genetic interactions. Genetic interactions are present when the effect of a perturbation (e.g. mutation or RNAi knockdown) depends on the
genetic background. To identify synthetic interactions with the KRAS locus, Luo et al. assayed the growth of an isogenic pair of DLD-1 cell lines after
RNAi knockdown. Schematic interaction plots (phenotypes not drawn to scale): (a) Control conditions: Cells carrying a mutant KRAS allele (KRAS
G13D, left) display increased proliferation (green) compared to isogenic KRAS wildtype (right) cells. (b) RNAi knockdown of COPB2 affects both KRAS
mutant and wildtype cells equally. Cell numbers are reduced to a similar degree (blue) by the presence of COPB2 siRNA (black symbols) compared to
a control siRNA (white symbols). There is no evidence of a genetic interaction and the lines connecting data points exposed to either control or COPB2
siRNAs are parallel. (c) PLK1 RNAi (black symbols) reduces the number of wt KRAS cells (right, blue line), but has a much stronger effect on cells
carrying the KRAS G13D allele (left, red line). The connecting lines of the interaction plot are not parallel, indicating the presence of a genetic
interaction.experiments cannot prove causal relationships owing to
potential hidden co-variates.
To shed light on genes and pathways required for KRAS-
driven oncogenesis, Luo et al. therefore chose a different,
complementary approach: the genomewide comparison
of RNAi phenotypes between isogenic cell lines [26].
Engineering differences: comparing isogenic
cell lines to reveal non-oncogene addiction
Instead of screening many different cell lines, Luo et al.
focused on DLD-1 cells, a well-established colon carci-
noma cell line harboring a heterozygous gain-of-function
mutation in KRAS (Figure 1b, Figure 2). To study
synthetic effects with this locus, the researchers took
advantage of a second, isogenic line lacking the mutant,
but still containing the wildtype KRAS allele [27]. They(Figure 1 Legend ) Experimental approaches to study genetic interactions. 
cells lines (shown as chromosomes in different colors) carrying either wildty
performed RNAi with an shRNA library (hairpins). The severity of growth phe
lines. RNAi phenotypes associated specifically with KRAS mutant lines includ
cell lines. Luo et al. compared DLD-1 cells (green chromosomes), engineered
as lightning bolt). RNAi phenotypes (symbolized by hairpins) were compared
gradient) of the KRAS mutant line for KRAS (red box) and PLK1 (yellow star) 
(HCT116). (c) Multiplex assays in isogenic cells lines. Muellner et al. introduce
helices) constructs together with molecular barcodes into MCF10A cells. Cel
for viability phenotypes. After deconvoluting the barcodes, a drug-sensitivity 
color gradient).
www.sciencedirect.com screened both lines in parallel with a pooled genome-
wide shRNA library and identified more than 350 genes,
whose silencing led to differential antiproliferative phe-
notypes [26]. For validation, Luo and co-workers
employed a sensitive multicolor competition assay and
could confirm 25% of the primary candidates, most of
which displayed specificity toward KRAS mutant cells in
a second, albeit related pair of isogenic lines. Strikingly,
with the exception of KRAS itself, none of these genes
had been described as an oncogene, supporting the
authors’ previous hypothesis that focusing on ‘non-onco-
gene addiction’ may offer a broad set of promising novel
drug targets [28].
Instead, the list of KRAS-synthetic lethal interactors
included regulators of mitosis (e.g. the kinase PLK1
(Figure 2)), ribosome biogenesis and translation, sumoy-(a) RNAi screening in a panel of cancer cell lines. Barbie et al. chose 19
pe or mutant KRAS alleles (mutant allele indicated as lightning bolt) and
notypes was quantified (blue color gradient) and compared across cell
ed KRAS (red box) and TBK1 (yellow star). (b) RNAi screening in isogenic
 to carry either a wildtype or mutant KRAS allele (mutant allele indicated
 and revealed a sensitivity (severity of phenotype indicated as blue color
knockdown, which could be confirmed in a second isogenic cell line pair
d 89 shRNA (shown as hairpins) or overexpression (indicated as double-
l were pooled and screened with 87 small molecules (symbolized as pills)
profile was obtained for each line (severity of phenotype indicated as blue
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hypothesized that KRAS oncogene activation may lead
to generally increased levels of mitotic stress and pre-
dicted that small-molecule inhibitors further disrupting
cell division would specifically affect cancer cells. Indeed,
clinically approved or experimental inhibitors of cell
division selectively impaired the growth of KRAS mutant
cells at low doses both in vitro and in xenograft models of
cancer [26].
The number of isogenic cell lines available from com-
mercial or academic sources is growing quickly, enabling
comparative high-throughput experiments focusing on
many genes, pathways and phenotypes [29,30,31]. Yet,
cancer cell lines frequently display genomic instability
and the targeted modification of individual loci and the
subsequent establishment of cell lines involves stringent
selection procedures. Researchers therefore need to care-
fully evaluate the degree of genetic and phenotypic
similarity between cells originally derived from the same
paternal line. Significant interactions between loci
observed in a specific genetic background can catalyze
novel mechanistic insights; their relevance for drug de-
velopment, requires validation in a broad panel of geneti-
cally diverse model systems.
From screens to maps: genetic interaction
landscapes
The systematic, high-throughput analysis of genetic
interactions in mammalian cells has only recently become
feasible. Yet, suppressor-screens and enhancer-screens
have long been a genetics staple in model organism such
as yeast [32], C. elegans [33,34] or Drosophila [35].
In particular, yeast geneticists have embraced the growth
and viability of cells as a general proxy for organismal
fitness, a complex quantitative phenotype, and con-
structed comprehensive interaction maps by systemati-
cally generating (nearly all possible) double-deletion
mutant combinations [36,37,38]. Besides identifying
individual synthetic lethal gene combinations, the sys-
tematic assembly of hundreds of interaction profiles into
large data matrices has enabled powerful correlative
analyses to delineate the complex functional networks
underlying cellular processes [36,39–41,42,43]. In
2010, the Boone and Andrews labs presented the largest
eukaryotic interaction map compiled to date, containing
quantitative interaction data for more than 5 million gene
pairs [37].
Recently, Bandyopadhyay et al. adapted this approach to
reveal how cells cope with DNA damage [44]. They
directly compared interactions maps recorded under nor-
mal or DNA-damage inducing conditions, a strategy
similar to identifying gene expression changes using
microarrays. Analyzing each dataset individually recov-
ered mainly ‘housekeeping interactions’ between genesCurrent Opinion in Genetics & Development 2012, 22:36–44 involved in chromatin biology (and previously observed
in other datasets [36,37]). Focusing on the differences,
on the other hand, specifically revealed known DNA
repair pathways and pinpointed several new regulators
of this well-characterized process.
The technical challenges of constructing similar maps in
higher organisms are formidable, for example, as the
number of possible pairwise gene-combinations grow
exponentially with genome size. Our own work has
provided a first indication that metazoan interaction maps
can be constructed from high-throughput, combinatorial
RNAi approaches [45] (Figure 3). To study the functional
interdependencies of signaling pathways in Drosophila
cells, we targeted 96 genes – each with two independent
RNAi reagents – and generated all ca. 18 000 possible
double-knockdown combinations. Recording three dis-
tinct quantitative phenotypes (cell growth, nuclear size
and DNA content) allowed us to identify more than 600
instances where the double-RNAi phenotype could not
be predicted from single perturbations using a multi-
plicative model [46]. Many of these genetic interactions
specifically affected only one of the assayed cellular
characteristics, highlighting the context-dependence of
functional connections (Figure 3). Correlating these inter-
action profiles across different signaling pathways pin-
pointed Cka/Striatin3 as novel positive regulator of the
Ras/MAPK cascade in fruitflies and in human cells [45].
The large number of pair-wise – let alone higher order –
interactions currently limits the scope of genetic inter-
action studies in metazoan cells and further technical
innovations are clearly required to experimentally map
interactions within mammalian-sized genomes. Future
experiments in mammalian cells might, for example, take
advantage of novel multiplexing strategies. For example,
Muellner et al. molecularly barcoded a panel of 89 engin-
eered isogenic cancer cell lines to survey over 6000 drug–
gene interactions in a highly multiplexed format [47]
(Figure 1c). The assay faithfully identified known as well
as novel interactions, revealing, for example, that
NOTCH1 activation can confer resistance to PI3K inhibi-
tors. Similar multiplex approaches could be applied to the
study of gene-gene interactions in the future, and might
be expanded further, for example, through next-gener-
ation sequencing based quantification strategies [48].
Outlook
Cancer pathways have been compared to a subway map,
featuring different lines (pathways), interchanges (cross-
talk) and stations (genes) (http://www.nature.com/nrc/
posters/subpathways/index.html). As for public transport,
the impact of a genetic aberration ‘‘is not restricted to the
activity of the gene product that carries it, but can spread
along the links of the network’’ [49]. For example, block-
ing a major subway line will have repercussions through-
out the network, as passengers try to find alternativewww.sciencedirect.com
From screens to maps Sandmann and Boutros 41
Figure 3
csw
csw
Gap1
Gap1
wt
RNA
i #1
Ras85D
pnt
p38b
Cka
Gap1
csw
cs
wt
RNA
i #1
RNAi #2
csw
wt
RNA
i #1
RNAi
 #2
Phenotypes
Cell 
num
ber
Nuc
leus
 size
DNA
  co
nten
t
(a)
(b)
(c)
Cell 
num
ber
Cell 
num
ber
csw
Gap1
Cka
p38b
pnt
Ras85D
csw
Gap1
Cka
p38b
pnt
Ras85D
Current Opinion in Genetics & Development
Multi-dimensional phenotyping. (a) Conventional RNAi screens typically assay the effect of perturbing the expression of single genes on one
phenotype (e.g. cell growth/viability). (b) By systematically combining RNAi reagents targeting two different genes (indicated in different colors) a two-
dimensional data matrix is be obtained, revealing genetic interactions as unexpected phenotypes that cannot be explained by combining the effects of
individual perturbations. (c) Multi-parametric analysis, for example, by fluorescence microscopy, yields information about different, independent
phenotypes, adding a third dimension to the data matrix. For each novel morphological feature, phenotype-specific single and interaction effects are
recovered, highlighting the context-dependence of functional connections. Further dimensions, for example, time, species or higher-order interactions
between more than two loci could be added.routes to their destination. Similarly, targeted cancer
therapies are rapidly thwarted by the emergence of drug
resistance, typically through unanticipated mechanisms
that were not obvious from the original wiring-diagrams.
For example, the B-RAF inhibitor PLX4032 (vemurafe-
nib) specifically blocks the oncogenic V600E variant of
the B-RAF gene, which is found in many cancers in-
cluding ca. 60% of melanomas [50]. Clinical trialswww.sciencedirect.com revealed very high early response rates to PLX4032 in
patients suffering from late-stage melanomas – followed
by the frequent development of drug-resistance [51,52].
Yet, none of the resistant tumors showed any changes at
the B-RAF(V600E) locus that could have explained the
secondary loss of treatment efficacy [53,54]. How had the
cells overcome their addiction to activated B-RAF?
Indeed, cancer cells outmaneuvered the drug through
at least two independent mechanisms: Johannessen et al.Current Opinion in Genetics & Development 2012, 22:36–44
42 Cancer genomicsdiscovered that upregulation of two other agonists of
MAPK-signaling, C-RAF and MAP3K8/COT, could
bypass the requirement for B-RAF by re-activating the
pathway downstream of the drug target [53]. At the same
time, Nazarian and colleagues observed that mutations in
yet another MAPK pathway component, NRAS, also
rendered tissue culture cells resistant to PLX4032. At
the same time, NRAS activation sensitized the cells
toward inhibitors of the downstream kinase MEK, pro-
viding novel opportunities for combinatorial therapeutic
interventions. In addition, the researchers also uncovered
that upregulation of an unrelated receptor-tyrosine
kinases (PDGFRb) could also provide pro-survival sig-
nals, offering an independent path toward PLX4032
resistance [54].
Currently, cancer researchers mainly appreciate genetic
interactions as a welcome means to an end, for example,
to kill cells through synthetic lethality. Yet, at the same
time systematic epistasis mapping offers an opportunity
to reveal the functional interaction landscape required for
the hallmark phenotypes of cancer. How does the cellular
wiring diagram change upon activation of the RAS onco-
gene? Which local tracks turn into essential main lines
upon transformation? What distinguishes the interaction
networks of early and late tumor stages?
A better understanding of the genetic interaction land-
scape in cancer will improve our ability to choose the best
possible treatment for individual patients, help identify
powerful drug combinations – and make progress toward
cancer therapies that are truly 20/20.
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